| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director, 10% Owner | Director | Director, Former 10% Owner
6 companies
Amir Nashat is Director at RNAC and has filed Form 4s across 6 companies. From May 2015 to September 2025, the filings on record show 7 open-market purchases and 17 sales. Amir Nashat's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $19.8M at current prices.
Historically, Amir Nashat's trades have earned a below-average insider score of 49/100 across 3 rated trades. Over a 12-month horizon, 66.7% of those trades were profitable, with an average 12-month return of +16.9%.
The biggest single holding is RNAC (~$17.2M) as Director. Net of sales, the RNAC filings show accumulation of 1,020,042 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Jan 25, 2019 | FATE Fate Therapeutics Inc | Director | Sell | 90,000 | $14.14 | $1,272,753.00 | -5.0% | |
| Jan 25, 2019 | RNAC Cartesian Therapeutics, Inc. | Director | Buy | 1,166,666 | $1.50 | $1,749,999.00 | +77.3% | |
| Jan 18, 2019 | FATE Fate Therapeutics Inc | Director | Sell | 39,483 | $16.28 | $642,834.38 | -2.2% | |
| Dec 20, 2018 | FATE Fate Therapeutics Inc | Director | Sell | 33,474 | $12.25 | $410,160.27 | -1.8% | |
| Dec 19, 2018 | FATE Fate Therapeutics Inc | Director | Sell | 91,210 | $13.40 | $1,222,592.34 | -4.7% | |
| Dec 13, 2018 | FATE Fate Therapeutics Inc | Director | Sell | 17,788 | $16.67 | $296,563.31 | -0.9% | |
| Dec 12, 2018 | FATE Fate Therapeutics Inc | Director | Sell | 425,000 | $16.78 | $7,132,690.00 | -17.8% | |
| Dec 11, 2018 | FATE Fate Therapeutics Inc | Director | Sell | 82,528 | $16.71 | $1,379,183.18 | -3.3% | |
| May 29, 2018 | SRRK Scholar Rock Holding Corp | Director, 10% Owner | Buy | 142,857 | $14.00 | $1,999,998.00 | +1,055% | |
| Sep 26, 2017 | RNAC Cartesian Therapeutics, Inc. | Director | Sell | 70,226 | $18.91 | $1,328,079.00 | -4.3% |